Cost-Effectiveness of Pembrolizumab Plus Chemotherapy Versus Pembrolizumab Monotherapy in Metastatic Non-Squamous and Squamous NSCLC Patients With PD-L1 Expression ≥ 50%

Objective To compare the cost-effectiveness of the combination of pembrolizumab and chemotherapy (Pembro+Chemo) versus pembrolizumab monotherapy (Pembro) as the first-line treatment for metastatic non-squamous and squamous non-small-cell lung cancer (NSCLC) with PD-L1expression ≥50%, respectively, f...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Qiao, Zhou, Zhen, Luo, Xia, Yi, Lidan, Peng, Liubao, Wan, Xiaomin, Tan, Chongqing, Zeng, Xiaohui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Pharmacology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784520/
https://www.ncbi.nlm.nih.gov/pubmed/35082679
http://dx.doi.org/10.3389/fphar.2021.803626

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8784520/
https://www.ncbi.nlm.nih.gov/pubmed/35082679
http://dx.doi.org/10.3389/fphar.2021.803626

Ejemplares similares